Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12656056 | 0.85 | CCR1 (0.41) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12625917 | 0.82 | PKM (0.51) | ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL24322690 | 0.81 | NPSR1 (0.51) | ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL12624157 | 0.81 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AGAA | |
| SCHEMBL24322524 | 0.81 | NPC1 (0.49) | ALDH1A1RAB9ASMN1; SMN2KMT2AGAA | |
| SCHEMBL12656059 | 0.81 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AUSP2 | |
| SCHEMBL22433209 | 0.76 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL10042201 | 0.76 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL24322801 | 0.76 | NPC1 (0.67) | ALDH1A1RAB9ASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL13035932 | 0.76 | POLB (0.39) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | ALDH1A1 4556/4885L3MBTL1 2569/4885RAB9A 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.